Regenerative Therapies in Neonatology: Clinical Perspectives

L. Gortner*, Ursula Felderhoff-Mueser, D. Monz, K. Bieback, H. Klueter, R. Jellema, B. W. Kramer, Brian M. Keller, I.K. Reiss, Peter A. Horn, Bernd Giebel

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Web of Science)

Abstract

Regenerative therapy based on stem cells is applied as standard therapy in pediatric oncology. Furthermore, they are frequently used to treat immunodeficiency disorders of infants. For severe neonatal diseases, e. g. hypoxic-ischemic encephalopathy in term neonates or bronchopulmonary dysplasia in preterm infants, animal models have been established. According to some first preclinical results stem cell administration appears as a promising tool to improve the clinical outcome in high-risk infants. Provided the benefit of regenerative therapies can further be evaluated in appropriate preclinical neonate models, carefully controlled clinical trials to assess the significance of regenerative therapies, such as autologous stem cell administration, are indicated.? Georg Thieme Verlag KG Stuttgart ? New York.
Original languageEnglish
Pages (from-to)233-240
JournalKlinische Padiatrie
Volume224
Issue number4
DOIs
Publication statusPublished - Jul 2012

Keywords

  • regenerative therapy
  • neonate
  • perinatal brain injury
  • bronchopulmonary dysplasia
  • cellular therapy

Cite this